Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies

Conventional type 1 dendritic cells (cDC1s) are superior in antigen cross-presentation and priming CD8(+) T cell anti-tumor immunity and thus, are a target of high interest for cancer immunotherapy. Type I interferon (IFN) is a potent inducer of antigen cross-presentation, but, unfortunately, shows...

Descripción completa

Detalles Bibliográficos
Autores principales: Noe, Paul, Wang, Joy H., Chung, Kyu, Cheng, Zhiyong, Field, Jessica J., Shen, Xiaomeng, Cortesio, Christa L., Pastuskovas, Cinthia V., Phee, Hyewon, Tarbell, Kristin V., Egen, Jackson G., Casbon, Amy-Jo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628189/
https://www.ncbi.nlm.nih.gov/pubmed/37942313
http://dx.doi.org/10.3389/fimmu.2023.1272055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628189/
https://www.ncbi.nlm.nih.gov/pubmed/37942313
http://dx.doi.org/10.3389/fimmu.2023.1272055

Ejemplares similares